Select Medical agrees to go-private buyout transaction

Select Medical ( (SEM) ) has provided an update.

On March 2, 2026, Select Medical Holdings Corporation announced it had entered a definitive agreement to be taken private by a consortium led by Executive Chairman and co‑founder Robert A. Ortenzio, senior executive Martin F. Jackson and private equity firm Welsh, Carson, Anderson & Stowe. The buyer group agreed to acquire all outstanding shares not already owned by the consortium for $16.50 per share in cash, implying an enterprise value of about $3.9 billion and representing premiums of roughly 18% to the company’s unaffected share price on November 24, 2025 and 25% to its 90‑day volume‑weighted average price.

A special committee of disinterested directors, advised by independent financial and legal advisers, unanimously deemed the deal fair to unaffiliated shareholders and recommended it to the board, which in turn unanimously backed the merger and urged investors to vote in favor. The transaction, expected to close in mid‑2026 pending approval by a majority of unaffiliated shareholders and customary antitrust and other regulatory clearances, would see certain insiders roll over about 11.8% of the equity, keep current management in place and leave existing debt outstanding, while resulting in Select Medical being delisted from the New York Stock Exchange and becoming a privately held company.

The financing package combines committed equity from WCAS and debt arranged by J.P. Morgan and Wells Fargo, and the merger agreement includes reverse and standard termination fees and specific‑performance provisions to enforce closing. For shareholders and creditors, the deal locks in a cash premium and signals a shift toward private ownership under sponsor control, potentially giving management more flexibility to pursue long‑term operational and strategic initiatives away from public markets, while concentrating governance influence with the lead executives and their private equity backer.

The most recent analyst rating on (SEM) stock is a Hold with a $16.50 price target. To see the full list of analyst forecasts on Select Medical stock, see the SEM Stock Forecast page.

Spark’s Take on SEM Stock

According to Spark, TipRanks’ AI Analyst, SEM is a Neutral.

The score is driven primarily by improving financial flexibility (notably deleveraging) and solid recent cash conversion, supported by constructive technical momentum. These positives are tempered by weakened profitability/margins, mixed earnings-call execution (especially outpatient weakness and the insurance cost hit), and only moderate valuation support.

To see Spark’s full report on SEM stock, click here.

More about Select Medical

Select Medical Holdings Corporation is one of the largest U.S. operators of critical illness recovery hospitals, rehabilitation hospitals and outpatient rehabilitation clinics. As of December 31, 2025, it ran 104 critical illness recovery hospitals in 28 states, 38 rehabilitation hospitals in 15 states and 1,917 outpatient rehab clinics across 39 states and Washington, D.C.

The company’s broad post-acute care footprint and focus on long-term acute care and rehabilitation services position it as a major player in the U.S. healthcare services market. Its scale and diversified facility network make it a key provider for patients requiring extended recovery and rehabilitation outside traditional acute-care hospital settings.

Average Trading Volume: 894,670

Technical Sentiment Signal: Buy

Current Market Cap: $1.86B

Find detailed analytics on SEM stock on TipRanks’ Stock Analysis page.